Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT-19 trial of mavrilimumab for COVID-19 pneumonia with hyperinflammation
2020-001795-15Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing Mavrilimumab + best standard of care with Placebo + best standard of care (2 arms). Primary endpoint: Time to absence of oxygen supplementation. Started Jun 2020; status: completed.
02
Drugs
mavrilimumab
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001795-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001795-15.